Michael J. Droller's research while affiliated with Mount Sinai Hospital and other places

... Cigarette smoke and its metabolites cause cancers of the bladder and kidney [22][23][24][25][26] resulting in the death of over 40 per cent of men in some countries of Eastern and Central Europe, and 17 per cent of women in the USA 27 . Risk factors for renal cell carcinoma include cigarette smoking presumably accelerating the risk in a patient whose first-degree relative is suffering with kidney cancer, that is, an elevated odds ratio above 2.5, 95 per cent C.I. 1.04-5.90 ...

... Unfortunately, despite the high specificity (approximately 86%) of cytopathology, the low sensitivity (48%) of urine cytology restricts its application (8), and it performs poorly in low-grade tumors (9). Recently, FDA has approved several urinary tests for diagnosis and monitoring of bladder cancer, including NMP22, ImmunoCyt/ uCyt+, UroVysion (fluorescent in situ hybridization), and bladder tumor antigen (BTA) (10). However, even though recent research demonstrated their good outcomes in the context of NMIBC, there is limited evidence to prove their effect on the situation of initial diagnosis (11). ...

... Recently, flexible cystoscopy was widely used in detecting bladder tumors and in the follow-up of bladder cancer patients [31,32]. Some studies reported that PDD-guided flexible cystoscopy could identifies smaller, more papillary tumors or flat CIS lesions in anaesthetized patients in the operating room than white light cystoscopy and rigid cystoscopes [33,34]. ...

... However, FC is likely to have a positive effect not only on prognosis but also on patient quality of life [30]. Recently, flexible cystoscopy was widely used in detecting bladder tumors and in the follow-up of bladder cancer patients [31,32]. Some studies reported that PDD-guided flexible cystoscopy could identifies smaller, more papillary tumors or flat CIS lesions in anaesthetized patients in the operating room than white light cystoscopy and rigid cystoscopes [33,34]. ...

... Despite radical treatment, around 50% of patients with invasive urothelial carcinoma will die from their disease [2]. Clinical evidence suggests that invasive tumours arise from carcinoma in situ (CIS), with 10-20% of CIS cystectomy specimens having microinvasion [3], up to 5% having nodal metastases [2], and 80% of untreated CIS cases progressing to muscle invasion [4]. Molecular studies support these clinical observations, with authors showing genetic similarities between CIS and invasive urothelial carcinoma, which contrast with non-invasive urothelial carcinomas [5][6][7]. ...

... Bladder cancer (Bc) is the sixth most prevalent type of cancer and the ninth most common cause of cancer mortality in men, with an estimated 573,000 new cases and 213,000 mortalities associated with Bc worldwide in 2020 (1). Although the current therapeutic strategies for non-muscular invasive Bc are acceptable, there is a lack of efficient treatment modalities and predictive markers for advanced Bc, which results in poor patient prognosis (2). In addition to surgery, cisplatin-based and neoadjuvant chemotherapy are the main treatment choices for advanced Bc (3). ...

... Los artículos de temas redundantes, con poco valor científico y reiterativos deben impedirse ser publicados. (2)(3)(4) ...

... One disadvantage of the PAP stain method is the requirement of a well-trained cytopathologist to clarify malignant cells according to their morphological features, such as a high nuclear/cytoplasmic ratio (N/ C), aggregating clusters, increased cellularity, irregular nuclear margins, hyperchromasia, and chromatin abnormality [5]. Nonetheless, there are still no standard criteria for the morphological evaluation, especially in an atypical status, which often confuses experienced cytopathologists [6,7]. Further, preserved or inadequate urine specimens, clinical conditions, and laboratory processing also influence the accuracy and quality of cytology. ...

... [13] Each research with the scores of at least 5 is regarded as high quality. [14] In case of any dispute on quality assessment, the investigators shall resolve it through discussion or come to an agreement by an arbiter. ...

... As these methods typically require fresh and not frozen tissue, we have initiated efforts to prospectively perform integrated single cell analysis of mixed histology bladder tumors. While we focused only on tumors with SqD in this study, there are other histologic variants of UC that warrant further investigation, in particular those that are associated with an aggressive clinical course, such as micropapillary, plasmacytoid, small cell and sarcomatoid carcinomas 11,12,64,65 . While patients with such tumors are often excluded from clinical trials of novel agents such as immune checkpoint inhibitors, the recent FDA-approvals of anti-PD-L1 and anti-PD1 antibodies for patients with bladder cancer should facilitate future biomarker studies to determine how the lineage plasticity observed in other histologic variants impacts the tumor microenvironment. ...